Hospital put woman in 'dirty' cubicle without food
A hospital has promised to improve its A&E after a family told the BBC their 77-year-old mother was left in a "dirty" cubicle for 22 hours.
Jill Clarke was admitted to Heartlands Hospital in Birmingham with a chest infection on 19 April, and her family claim she was left alone all night without any food or drink.
Her son Peter said that when his mother was finally seen, she was given a meal he would not feed "to a pig" and was later left bruised by a ward nurse.
A spokesperson for the hospital apologised and said it was experiencing high levels of demand.
Ms Clarke, from Shirley, requires full time care and lives with chronic obstructive pulmonary disease (COPD), which causes breathing difficulties.
She was discharged from Heartlands on 23 April, and is recovering from the infection.
But her family have been left furious by her treatment during the four-day stay, and believe the current state of the hospital is unacceptable.
Mr Clarke claimed his mother had been put on a trolley with dried blood on, and then left in a "filthy" A&E cubicle with used syringes on a nearby window.
The 45-year-old shared pictures of a meagre-looking meal his mother was apparently given, despite not having been offered anything to eat or drink for a long time.
"I wouldn't have fed that meal to a pig," he said.
"It was disgusting and they were giving that to a 77-year-old lady who hadn't eaten in 24 hours."
Mr Clarke further claimed his mother was hurt by a nurse who had been unable to put her cannula in properly.
It happened after Ms Clarke was taken from the cubicle and put onto a ward, with a photo appearing to show her with a bruised arm.
The hospital did not comment on this claim specifically.
The family have made a formal complaint.
Mr Clarke explained his relatives had a proud history of working in the NHS.
For many years, he was employed as a switchboard operator and a porter at West Middlesex University Hospital in London.
The family, who now live in the West Midlands, have had to take Ms Clarke to Heartlands three times in the past five months.
While Mr Clarke said April's visit was the worst, he believed the service was consistently poor.
"It's every single day," he said. "It needs a complete shut down and a thorough deep clean.
"If [my] old boss had walked into A&E at Heartlands and did a quality control check, he would have shut the A&E down."
Heartlands Hospital is run by University Hospitals Birmingham.
The trust has found itself under scrutiny since being heavily criticised in a March 2023 report over cases of bullying and a toxic environment.
In February last year, inspectors said urgent and emergency care at Heartlands had improved from inadequate to requires improvement.
A further Care Quality Commission probe in November found concerns about surgery and medical services at the hospital were "unfounded".
A Heartlands Hospital statement said all concerns were taken seriously and were being looked into appropriately.
"We are sorry to hear about Mrs Clarke's experience and we're grateful to her son Mr Clarke, for raising their concerns about her care," a spokesperson said.
"Our emergency department is experiencing high levels of demand which can make maintaining the environment challenging at very busy times.
"We have now instigated an intensive programme to improve the environment for all our patients."
Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
Bullying and toxic culture at NHS trust - report
Safety fears remain at 'toxic' NHS trust
Hospital concerns unfounded - report
University Hospitals Birmingham
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article "Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial" reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, "Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation" describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, "A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier" reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: "It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. "The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. "We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases." Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: "These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation." About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030. View source version on Contacts EpiEndo Pharmaceuticals: Maria Bech, CEO+354 454 0090 Vigo Consulting (media relations):Rozi Morris+44 20 7390 0230epiendo@ Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
The Top Food Safety Mistake You're Making With Produce
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." For some, the act of chopping, peeling and coring vegetables for half an hour after a long day can be meditative. For the rest of us, however, it's a total drag — and truly, nothing makes us crave takeout like the thought of prepping mirepoix vegetables on a work night. Our solution? Do it ahead of time. As any cook or recipe developer will tell you, tackling all (or most) of your produce prep in advance is one of the best ways to streamline the cooking process, so you can make a fresh, flavorful meal — or enjoy an easy, healthy snack — on the fly. There is, however, one small catch when it comes to pre-peeling or chopping your fresh fruit and vegetables: The moment you cut into them, they become much more vulnerable to nutrient loss, oxidation and harmful pathogens — and this only worsens if your produce sits out on the counter. So the next time you think about chopping up that beautiful lettuce for your salad be sure to avoid these food safety mistakes. Instead, learn how to properly store your prepped fruit and vegetables so they stay flavorful, fresh and ready to incorporate into your huge fans of leaving the skin on fresh produce like carrots, cucumbers, and potatoes. Not only is it a rich source of fiber and antioxidants, but the skin can also add extra flavor and texture to meals. Of course, that skin plays another vital role — it protects what's inside. 'Once fruits and vegetables are cut, peeled or processed, their protective outer layers are compromised,' says food safety expert Dr. Darin Detwiler. This leaves them vulnerable to pathogens like salmonella, listeria, and E. coli. Produce like apples and avocados will also quickly begin to oxidize, which — while harmless — is still less than appetizing. Before you even pick up a knife or peeler, make sure to give your produce a thorough scrub. Otherwise, you may contaminate your fruits and vegetables before they even get to the fridge. 'Bacteria on the outer surface can transfer inside during cutting,' says Dr. Detwiler. Waiting until after the produce is cut or peeled to wash it can be worse than not washing it all, as 'water can actually spread bacteria inward' once the skin is broken, he explains. To wash your produce, rinse under cold running water, using a designated brush to remove dirt or wax. Never use soap or bleach! Fruits and vegetables are porous, meaning they'll absorb anything you put on them, even after rinsing. If your produce is especially dirty, or you're worried about pesticides, you can also try a cold-water soak by adding 1 tsp of baking soda to every 2 cups of water (use enough water to fully submerge your produce), then soaking for 12 to 15 minutes. However you choose to wash your produce, make sure to dry it thoroughly before storing — and remember that all produce spoils faster after it's been washed, so it's best to wash it right before you're ready to use it.$5.60 at When you finally get to chopping, make sure your work station is thoroughly clean and sanitized. Good Housekeeping Recipe Editor Susan Choung recommends using a different cutting board for produce than the one you use for raw meat or seafood, which is important for preventing cross-contamination (especially if you're planning on serving produce raw). Alternatively, you can wash your cutting board with hot water and soap before using it to cut fruits and vegetables. Once you've done the hard work of selecting, cleaning, and prepping your fresh farmers' market finds, it's time to pop it straight in the produce Well, not exactly. While Dr. Detwiler recommends promptly refrigerating most produce after peeling or cutting — making sure the temperature stays at 40°F or below — not all fruits and vegetables get stored the same way, nor do they have the same shelf life. Cantaloupes, for example, are at higher risk for contamination than other fruits, says Dr. Detwiler. And as such, they should be eaten immediately once cut. Cut fruits and vegetables should never be left at room temperature for more than two hours — or one hour if the room is hotter than 90 degrees Fahrenheit, he says. Clearly labeling and dating containers is another way to ensure that fruits and vegetables get used up. Below, you can find Dr. Detwiler's recommendations for storing common fruits and vegetables after prepping, as well as an estimation of their typical shelf life. Apples: 3–5 days; use lemon juice to prevent browning Bananas: 1-2 days once peeled, though best eaten fresh; may be frozen Berries (e.g. strawberries, blueberries, and raspberries) 1–3 days; should be stored loosely covered and unwashed until ready to eat Citrus fruits: 3–4 days when sealed Melons (e.g. watermelon): 3–4 days; should be refrigerated immediately. Cantaloupe: should be consumed immediately Mangoes, papayas, and pineapples: 3–5 days; should be sealed in airtight containers Avocados: 1–2 days if covered tightly with the pit left in place Leafy greens (e.g. lettuce and spinach): 3–5 days when dried and stored with a paper towel Carrots: 1–2 weeks when submerged in water (which should be changed every 2–3 days) Bell peppers: 3–5 days in a resealable bag or airtight container Cucumbers: 1–3 days when wrapped in paper towels Tomatoes: 2–3 days if stored cut-side down Onions: 7–10 days when tightly wrapped Garlic (peeled): one week in a sealed container Mushrooms: 1–2 days; should be kept in a paper or ventilated container Broccoli and cauliflower: 3–5 days in sealed bags Celery: 1–2 weeks when wrapped in foil or submerged in water (with regular water changes) No matter how hard you try, you'll inevitably encounter a moldy or rotten piece of produce; it's simply a fact of life. The important thing is to quickly identify and toss the offending fruit or vegetable. 'If produce looks slimy, smells sour, or shows signs of mold, throw it out.' Finally, if you don't think you'll be able to use up fresh produce right away, try freezing it: Frozen berries, bananas, and leafy greens are great for adding to smoothies and soups and are often cheaper than the store-bought versions. Note it's better to freeze produce closer to the date you bought it from the store. If you waited a few days, instead, try cooking to extend its shelf life — throw it into a stir-fry, fold into a frittata or make a jam. You Might Also Like 67 Best Gifts for Women That'll Make Her Smile The Best Pillows for Every Type of Sleeper
Business Wire
2 hours ago
- Business Wire
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article 'Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial' reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, 'Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation' describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, 'A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier ' reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: 'It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. 'The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. 'We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases.' Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: 'These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation.' About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.
